%0 Journal Article %T EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report %A Zhou, Tong %A Zhou, Xiaoyue %A Li, Peng %A Qi, Chuang %A Ling, Yang %J Journal of Thoracic Disease %D 2018 %B 2018 %9 %! EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report %K %X EGFR mutation is an important driving event in the development of non-small cell lung cancer (NSCLC), especially in pathologically diagnosed lung adenocarcinoma and non-smoking women in Asia (1). Compared with traditional platinum-containing chemotherapy, NSCLC patients with certain EGFR sensitive mutations showed higher clinical response to EGFR tyrosine kinase inhibitors (EGFR-TKIs), as confirmed by a series of phase III clinical trials, such as WJTOG3405, OPTIMAL, LUXLUNG6 and so on. %U https://jtd.amegroups.org/article/view/25921 %V 10 %N 12 %P E802-E805 %@ 2077-6624